| abstract |
This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an acetylcholinesterase inhibitor. Multiple sclerosis is treated by a combination of an ADNF III polypeptide and glatiramer acetate. Schizophrenia is treated with a combination of an ADNF III peptide and an antipsychotic drug, selected from Aripiprazole, Clozapine, Ziprasidone, Resperidone, Quetiapine, and Olanzapine. |